Guidance

SSRIs and SNRIs: use and safety

Guidance on the use and side effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs), their safety, use in pregnancy and the risk of suicidal behaviour.

From:
Medicines and Healthcare products Regulatory Agency
Published
18 December 2014

Documents

Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs): use and safety

HTML

Details

This page was published in 2014 and remains online only as a historical record.  For updated information about these medicines, please consult the relevant Summary of Product Characteristics and Patient Information Leaflet on the MHRA’s products page.

The Medicines and Healthcare Products Regulatory Agency (MHRA) guidance for healthcare professionals covers:

  • risk of suicidal behaviour
  • withdrawal reactions
  • use in pregnancy
  • effects on tamoxifen effectiveness
  • interaction with methylthioninium chloride
Published 18 December 2014

Related content